Pharmacology
- 6-Year Follow-Up Data For Dasatinib Demonstrates 71 Percent Overall Survival In Chronic-Phase Chronic Myeloid Leukemia
-
Results Presented at the 17th Congress of the European Hematology Association by Bristol-Myers Squibb Company and Otsuka Pharmaceutical Europe Ltd., said six-year follow-up results from a Phase 3 randomized, open-label, dose-optimisation study of SPRYCEL( ...
Article - Anna Ohlden - Jun 17 2012 - 11:15am
- An International Call To Action To Alleviate Drug Shortages
-
Society is in a tough spot. Drug companies are culturally vilified and routinely sued when things go bad- all in return for only a few years of profitability before anyone can make the new drugs they develop- the FDA is constantly under pressure to expedi ...
Article - News Staff - Jun 18 2012 - 1:00pm
- Hyperparathyroidism Treatments To Decline Due To Fewer Product Launches And Increased Generic Erosion
-
GBI Research, a business intelligence provider, has released its latest research, 'Bone Metabolism Therapeutics Market to 2018- Hyperparathyroidism Sector to Decline in the Absence of New Product Launches and Increased Generic Erosion for Zemplar, He ...
Article - Anna Ohlden - Jun 19 2012 - 4:00pm
- The Secret History Of Pain Killers
-
Looking at the latest statistics, it’s hard to miss one compelling trend: The over-prescription of painkillers is slowly but surely eclipsing the problem of illegal drugs. There are, of course, the usual culprits in this disturbing trend- from HMOs and the ...
Article - Greg Critser - Jun 20 2012 - 12:42pm
- Positive CHMP Opinion For Teduglutide For Patients With Short Bowel Syndrome
-
Takeda Pharmaceutical Company Limited and NPS Pharmaceuticals, Inc., jointly announced today that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion, recommending the granting of a mar ...
Article - Anna Ohlden - Jun 23 2012 - 7:30am
- Ferumoxytol Receives European Authorziation For Treatment Of Iron Deficiency Anemia In Chronic Kidney Disease
-
Takeda Pharmaceutical Company Limited and AMAG Pharmaceuticals, Inc. today announced the granting of marketing authorization by the European Commission (EC) for ferumoxytol, a new intravenous (IV) iron therapy to treat iron deficiency anemia (IDA) in adul ...
Article - Anna Ohlden - Jun 24 2012 - 5:30am
- Miracle Cure Of The Week: Daffodils May Fix Depression
-
Plant compounds from a South African daffodil may be used to treat depression, according to a University of Copenhagen study, where they tested those substance in a laboratory model of the blood-brain barrier. Substances from the South African plant specie ...
Article - News Staff - Jun 22 2012 - 3:30pm
- Positive Opinion For HUMIRA® In Non-radiographic Axial Spondyloarthritis From EMA's CHMP
-
Abbott announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for HUMIRA (adalimumab) in adults with severe axial spondyloarthritis (axSpA) who have no X-ray evidence of structural damage. Upon fina ...
Article - Anna Ohlden - Jun 26 2012 - 1:32am
- VELCADE Receives Positive EU Regulatory Recommendation For Subcutaneous Administration
-
Janssen-Cilag International NV (Janssen) announced today that the Committee for Medical Products for Human Use (CHMP) of the European Medicines Agency (EMA) has granted a positive opinion recommending approval of subcutaneous (under the skin) administrati ...
Article - Anna Ohlden - Jun 27 2012 - 1:30am
- Shire's VPRIV® Shows Significant Improvement In Gaucher-Related Bone Disease
-
In a head-to-head trial between VPRIV and Cerezyme(R) (imiglucerase), only patients treated with VPRIV experienced statistically significant improvement in lumbar spine bone mineral density at 9 months Shire plc today presented new data that show VPRIV ...
Article - Anna Ohlden - Jun 28 2012 - 4:00pm